Products

EchoGo Pro
Ultromics
Cardiology AI
EchoGo Pro is an FDA-cleared, AI-powered cloud solution by Ultromics that automates stress echocardiography analysis to improve the diagnosis of coronary artery disease, providing near-instant, accurate reports.

See all 1 product →

About Ultromics

Ultromics is a healthcare AI company that specializes in developing AI-powered diagnostic solutions for cardiovascular diseases, particularly focusing on echocardiography. Their flagship product, EchoGo, utilizes advanced machine learning and deep learning algorithms to analyze echocardiograms, aiming to improve the accuracy and efficiency of diagnosing complex heart conditions. The platform is designed to integrate seamlessly into existing clinical workflows, providing clinicians with quantitative reports on cardiac function and structure without requiring new hardware.

The company’s technology is particularly focused on detecting challenging and often underdiagnosed forms of heart disease, such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. By extracting subtle disease signals from routine echocardiograms, Ultromics aims to enable earlier and more accurate diagnoses, leading to timely interventions and improved patient outcomes. Ultromics’ solutions have received FDA clearance and are being adopted by major U.S. health systems and research institutions, including the Mayo Clinic, University of Chicago Medicine, and Northwestern.

Focus Areas

AI-driven cardiology solutions echocardiography analysis heart failure detection cardiac amyloidosis detection cardiovascular disease diagnosis machine learning in healthcare

Business Intelligence

TechnologyCloud-native (Microsoft Azure), AI operating system, machine learning, deep learning, DICOM workflow integration

What Physicians Need to Know

AI-Driven Echocardiography Analysis
Ultromics specializes in using AI to analyze echocardiograms, providing rapid and reproducible measurements of left ventricular volumes, ejection fraction (EF), and global longitudinal strain (GLS). This helps in detecting subtle disease signals that might be missed by manual interpretation.
Heart Failure Detection (HFpEF)
Their FDA-cleared EchoGo® Heart Failure platform is designed to identify heart failure with preserved ejection fraction (HFpEF) from routine echocardiograms. It provides a continuous probability score reflecting the likelihood of HFpEF, aiding in earlier diagnosis of this often-underrecognized condition.
Cardiac Amyloidosis Detection
Ultromics offers EchoGo® Amyloidosis, an FDA-cleared AI tool for screening cardiac amyloidosis, a rare and progressive type of heart failure. This tool helps identify findings suggestive of cardiac amyloidosis, even when subtle or inconclusive, supporting earlier recognition and intervention.
Cardiovascular Disease Diagnosis
By leveraging AI, Ultromics enhances overall cardiovascular disease detection, enabling clinicians to identify complex conditions early from routine echocardiograms for improved patient outcomes.
Machine Learning in Healthcare
Ultromics' solutions are built on over a decade of cardiovascular research and clinical validation from institutions like the University of Oxford and Mayo Clinic, combining deep clinical expertise with world-class AI research.
Key Differentiators
Ultromics' key differentiators include multiple FDA clearances and Breakthrough Device Designations, evidence cited in the 2025 ASE Diastology Guidelines, and a CMS Category III CPT code (0932T) for EchoGo® Heart Failure, supporting reimbursement. Their AI models are clinically validated and proven in real-world practice with over 530,000 echocardiograms analyzed.
Technology Stack
Ultromics utilizes a cloud-based AI platform, specifically leveraging Microsoft Azure, to provide high-quality, rapid interpretation of echocardiograms. Their technology is designed for seamless integration into existing echocardiography workflows, including PACS, CVIS, and EMR systems.
Physician Tip

For physicians, Ultromics' solutions offer augmentative AI-assisted analysis that integrates seamlessly into existing echocardiography workflows without requiring changes to scanning protocols or acquisition. The AI findings are typically available within 20 minutes, delivered directly into PACS and EMR systems, allowing for review alongside routine studies. This can help in earlier identification of HFpEF and cardiac amyloidosis, even when findings are subtle, reducing inter-operator variability and potentially leading to earlier intervention and improved patient outcomes. The platform is designed to support clinical interpretation and not as a standalone diagnostic tool.

Ultromics' AI models are delivered through a single integrated workflow platform and are designed to integrate with existing ultrasound and PACS environments, including vendors like Fujifilm Synapse®, Sectra, Fuji Film, Hearlab, Optum, Sciimage, Interlad, and Philips. AI findings are returned directly into PACS, CVIS, and EMR systems, making results available where clinicians already work without additional logins or software.

Products by Ultromics

1 product in the directory

EchoGo Pro
Ultromics
Cardiology AI
EchoGo Pro is an FDA-cleared, AI-powered cloud solution by Ultromics that automates stress echocardiography analysis to improve the diagnosis of coronary artery disease, providing near-instant, accurate reports.

What the Web Says

Ultromics is a company that provides AI-powered diagnostic tools for echocardiography, with FDA-cleared solutions for detecting heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis. Their flagship product, EchoGo, analyzes echo video clips using machine learning to identify subtle patterns and delivers structured reports within 20 minutes. While their product receives positive attention for its innovative use of AI in healthcare, employer reviews are scarce and mixed, with some concerns about job security and company size.

Overall: Mixed

Strengths

  • AI-powered diagnostic tools for echocardiography
  • FDA-cleared solutions for HFpEF and cardiac amyloidosis
  • EchoGo platform provides rapid analysis of echocardiograms
  • Identifies subtle patterns missed by human interpretation
  • Integrates with existing imaging infrastructure
  • Potential to find hidden diseases and clear backlogs in echo labs

Limitations

  • Limited employer reviews available
  • One employer review mentions constant threat of company being sold or downsizing
  • Company size is relatively small (2-10 employees according to some sources, 51-200 according to others)
  • Challenges with adding AI tools to echocardiography, such as accuracy, training, or trust in the technology, have been raised in discussions

Based on reviews from: Elion Health, Indeed.com, Healthcare Industry Reviews, Reddit, SimplyHired

Last updated: 2026-10-20

Videos

News, demos, and interviews about Ultromics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Ultromics →

View all on YouTube

Press & Coverage

Ultromics Press Releases
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
Ultromics secured $55 million in Series C funding to expand the nationwide rollout of its FDA-cleared AI platform, EchoGo®, which detects heart failure earlier from a single echo scan. This funding will help address the global heart failure crisis by enabling earlier diagnosis and transforming patient care.
2025-07
Ultromics Press Releases
Ultromics Named a WIRED 2025 Trailblazer
Ultromics has been recognized as a WIRED 2025 Trailblazer for its pioneering work in AI for cardiovascular imaging, particularly with its FDA-cleared EchoGo® platform that aims to tackle the global heart failure crisis.
2026-07
PR Newswire
Ultromics Obtains Breakthrough Device FDA Clearance for its Cardiac Amyloidosis Screening Device Through the Total Product Lifecycle Advisory Program
Ultromics received FDA Breakthrough Device Clearance for its EchoGo® Amyloidosis screening device, which uses AI to detect cardiac amyloidosis from a single echocardiogram image. This clearance is a significant step towards earlier diagnosis and treatment of this often-underdiagnosed disease.
2024-11
Ultromics Press Releases
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
Ultromics was granted FDA Breakthrough Device Designation for its AI-enhanced tool, EchoGo Amyloidosis, designed to detect cardiac amyloidosis using echocardiograms. This designation aims to accelerate the review process for products addressing debilitating or life-threatening conditions.
2023-04
Ultromics Press Releases
Landmark Study Shows Ultromics' EchoGo® Amyloidosis Significantly Improves Detection of Cardiac Amyloidosis with Echocardiography
A large-scale, multi-center international study published in the European Heart Journal demonstrated that Ultromics' AI-powered tool, EchoGo® Amyloidosis, significantly improves the screening of cardiac amyloidosis from standard echocardiograms. This is the first FDA-cleared AI screening tool for this condition.
2025-07
Ultromics Press Releases
Ultromics receives FDA clearance for its breakthrough device for HFpEF detection
Ultromics received FDA clearance for its EchoGo® Heart Failure device, an AI-powered tool developed in collaboration with Mayo Clinic, which accurately detects Heart Failure with preserved Ejection Fraction (HFpEF) from a single echocardiogram image.
2022-12
Ultromics Press Releases
Ultromics Secures Strategic Investment from the American Heart Association's Go Red for Women Venture Fund
Ultromics received a strategic investment from the American Heart Association's Go Red for Women Venture Fund to accelerate its mission of making early identification of heart failure a standard part of cardiac care. The funding supports the expansion of its FDA-cleared AI platform, EchoGo Heart Failure.
2025-12
Ultromics Press Releases
Ultromics granted CPT III reimbursement code for EchoGo® Heart Failure
Ultromics announced that the American Medical Association (AMA) has issued a Category III Current Procedural Terminology (CPT) code for EchoGo® Heart Failure, facilitating clinical reimbursement for its AI-powered diagnostic tool.
2024-07

Frequently Asked Questions

Ultromics specializes in AI solutions for echocardiography analysis, aiming to enhance the accuracy and efficiency of cardiac diagnoses. Their products, such as EchoGo® Heart Failure and EchoGo® Amyloidosis, utilize AI to automate and standardize the interpretation of echocardiograms, potentially leading to earlier and more accurate detection of conditions like heart failure and cardiac amyloidosis than traditional visual assessment.
Ultromics validates its machine learning algorithms through extensive clinical trials and collaborations with leading cardiology institutions. Their solutions are built on large, diverse datasets of echocardiograms and are designed to provide consistent, objective analysis, reducing inter-observer variability and improving diagnostic confidence.
Ultromics' products, including EchoGo® Heart Failure and EchoGo® Amyloidosis, are CE-marked and FDA-cleared, demonstrating their adherence to stringent regulatory standards for medical devices in both European and United States markets. This ensures their solutions meet established safety and performance requirements for clinical use.
While specific pricing details are not publicly disclosed and would require direct consultation with Ultromics, their solutions are designed to offer a strong return on investment by improving diagnostic efficiency, reducing misdiagnosis rates, and potentially optimizing patient management pathways. Healthcare providers can expect to discuss tailored pricing models based on their institutional needs and scale of use.
Ultromics offers comprehensive support and training programs to facilitate seamless integration of their AI platforms into existing clinical workflows. This includes technical assistance for IT integration, hands-on training for cardiologists and sonographers, and ongoing customer support to ensure optimal utilization and performance of their solutions.
Ultromics has forged strategic partnerships with leading pharmaceutical companies, medical device manufacturers, and academic research institutions. These collaborations aim to further validate their technology, expand their research capabilities, and integrate their AI solutions within broader cardiovascular care ecosystems.
Ultromics is committed to continuously advancing AI in cardiology, with a long-term vision to expand their diagnostic capabilities across a wider spectrum of cardiovascular diseases. They are actively engaged in research and development to introduce new AI-driven solutions and enhance existing features, further improving the precision and accessibility of cardiac diagnostics.

Related Companies

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

Qure.ai is a leading healthcare AI company that leverages deep learning and artificial intelligence to revolutionize medical imaging diagnostics and make healthcare more accessible and affordable globally. The company develops AI-powered solutions for interpreting X-rays and CT scans, addressing critical health needs in areas such as lung, musculoskeletal, cardiovascular, and neurocritical health. Their technology assists […]

Deep Bio is a healthcare AI company that develops deep learning-based cancer diagnostic support software, aiming to advance patient outcomes by empowering clinicians with innovative technology. Their mission is to provide tools that enable medical professionals to make critical decisions, ultimately enhancing healthcare delivery and allowing clinicians to focus more on patient care. The company’s […]

CortiCare is a healthcare AI company specializing in neuro telemetry and remote patient monitoring, primarily focusing on electroencephalogram (EEG) services. The company provides telehealth services and an EEG brain monitoring platform to neurology and critical care areas within hospitals, including ICUs, NICUs, PICUs, and EMUs. Their services aim to enhance the neurological assessment of adult, […]

CapsoVision is a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (AI) technologies for capsule endoscopy solutions. Their primary goal is to identify abnormalities of the gastrointestinal (GI) tract for diagnostic and screening purposes. [7] Their flagship product, the CapsoCam Plus system, is a single-use capsule endoscope equipped with four cameras, providing […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.